Elisabetta Bonzano MD, PhD

📌 Primary Results From ASCENT-03 ✨

PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70

Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG

📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨

🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS

Proffered paper session 2

#ESMO25 @oncoalert.bsky.social #OncoalertAF

📌OncoAlert AF #ESMO25
@oncoalert.bsky.social
See you in Berlin 🇩🇪

YouTube video by OncoAlert 360 The OncoAlert Weekly Round Up Sept 25-Oct 2, 2025 : DESTINY Breast05 / NATALEE / PROGRESS

The OncoAlert Weekly Round Up is Now Out
youtu.be/CSfTz6Iftek

@realbowtiedoc.bsky.social
@fernandoonco.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@biagioricciutimd.bsky.social
@erikahamilton9.bsky.social

The OncoAlert🚨NEWSLETTER
⭐️COMPLETE #ASCO25 EDITION

⭐️REGISTER
👉 oncoalert360.com
👉 buff.ly/48Xpgz0

@erikahamilton9.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@hoperugo.bsky.social

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

🔗nejm.org/doi/full/10.10…

👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)

@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc

@darcyburbage.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@elisabettabonzano.bsky.social
@kjankovic.bsky.social
@elisaagostinetto.bsky.social
@joanmancusombc.bsky.social

📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc

📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer.
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3

📌 Highlights of the Day II
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 Do We "Node" What to Do About the Axilla❓
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 LBA Session❗️
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻

👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%

@oncoalert.bsky.social #OncoAlertAF #ASCO25

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@elisaagostinetto.bsky.social
‬
@erikahamilton9.bsky.social
‬
@drsgraff.bsky.social
‬
@elisabettabonzano.bsky.social
‬

📌Great discussant #ESTRO25

prof @icromeattini.bsky.social 👏🏻👏🏻

✨ Late-Breaking Papers ✨

👉🏻10y FAST-Forward randomised trial
👉🏻 DBCG Skagen trial 1
@oncoalert.bsky.social

@biagioricciutimd.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@elisabettabonzano.bsky.social
@kjankovic.bsky.social
@elisaagostinetto.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social

A Great Presentation by Dr. Hope Rugo 🇺🇸 on Advanced Triple Negative #BreastCancer 🚨 vimeo.com/1077243852?s...

Get caught up on the TOP trials and those that impacted Clinical Practice in less than 2⃣0⃣min

You Can find ALL video here, Free & On Demand👇 oncoalert360.com/oncoalert128...

📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠

mdpi.com/1422-0067/26/8…

👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.social #OncoAlertAF

The @oncoalert.bsky.social 🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/l_jcTe69cCs

📌 Awareness of genomic testing among patients with breast cancer in Europe 🧬

www.sciencedirect.com/science/arti...

@oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social
@csabadegi.bsky.social

📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
@oncoalert.bsky.social #OncoAlertAF

thegreenjournal.com/article/S0167-…

📌 Selective Elimination of Breast Surgery for Invasive Breast Cancer
A Nonrandomized Clinical Trial

jamanetwork.com/journals/jam...
@oncoalert.bsky.social

📌 Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer

jamanetwork.com/journals/jam...

@oncoalert.bsky.social

📌 Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism

molecularcancer.biomedcentral.com/articles/10.11…
@oncoalert.bsky.social

📌 Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer
👉🏻 addressing lifestyle factors to improve patient outcomes and quality of life 🚭

ro-journal.biomedcentral.com/articles/10.11…

@oncoalert.bsky.social

Top Advances in SCLC In this latest episode of the VJOncoAlert Journal Club, Misty Shields, MD, PhD, Indiana University Simon Comprehensive Cancer Center, Indianapolis,...

🚨New #VJOncoAlertJournalClub! with @oncoalert.bsky.social 🗞️

Breaking down the latest in #oncology – every week!

Join Misty Shields as she shares the latest advances in #SCLC, including the game-changing #ADRIATIC trial, DLL3-targeting therapies & more

www.vjoncology.com/video/ayudqc...

📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation

sciencedirect.com/science/articl…
@oncoalert.bsky.social #OncoAlertAF

Development of a prediction model for ctDNA detection (Cir-Predict) in #BreastCancer

buff.ly/6Ixw2Jy

This study developed a prediction model, Cir-Predict, to assess the detectability of circulating tumor DNA (ctDNA) in breast cancer patients

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival

link.springer.com/article/10.1...

Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients.
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social

📌 Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial
redjournal.org/article/S0360-…
@oncoalert.bsky.social